Correlation Between Acrivon Therapeutics, and Gracell Biotechnologies

Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Gracell Biotechnologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Gracell Biotechnologies into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Acrivon Therapeutics, Common and Gracell Biotechnologies, you can compare the effects of market volatilities on Acrivon Therapeutics, and Gracell Biotechnologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Gracell Biotechnologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Gracell Biotechnologies.

Diversification Opportunities for Acrivon Therapeutics, and Gracell Biotechnologies

0.0

Correlation Coefficient

Acrivon Therapeutics,  Gracell Biotechnologies

Pay attention - limited upside

The 3 months correlation between Acrivon and Gracell is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Gracell Biotechnologies in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Gracell Biotechnologies and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Gracell Biotechnologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Gracell Biotechnologies has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Gracell Biotechnologies go up and down completely randomly.

Pair Corralation between Acrivon Therapeutics, and Gracell Biotechnologies

If you would invest (100.00) in Gracell Biotechnologies on December 20, 2024 and sell it today you would earn a total of  100.00  from holding Gracell Biotechnologies or generate -100.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	0.0%
Values	Daily Returns

Acrivon Therapeutics, Common  vs.  Gracell Biotechnologies

Acrivon Therapeutics,

Risk-Adjusted Performance

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.

Gracell Biotechnologies

Risk-Adjusted Performance

Very Weak

Over the last 90 days Gracell Biotechnologies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent fundamental indicators, Gracell Biotechnologies is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors.

Pair Trading with Acrivon Therapeutics, and Gracell Biotechnologies

The main advantage of trading using opposite Acrivon Therapeutics, and Gracell Biotechnologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Gracell Biotechnologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gracell Biotechnologies will offset losses from the drop in Gracell Biotechnologies' long position.

The idea behind Acrivon Therapeutics, Common and Gracell Biotechnologies pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.